Clinical trials: Cancer of the Esophagus
Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus
Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus
The purpose of this study is the determine whether a new compound, called lapatinib, can be effective in shrinking cancerous tumors of the esophagus that have recurred or spread somewhere else in the body.
- Trial name
- NCT00239200
- Testing
- Lapatinib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Michigan Rogel Cancer Center
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Organoid, Esophageal Cancer
Organoid Based Response Prediction in Esophageal Cancer
Rationale: Current standard treatment of localized esophageal cancer (EC) with neoadjuvant chemoradiotherapy (nCRT) followed by esophagectomy with curative intent results in 30% complete, 40-60% partial and 20% no-response at…
- Conditions
- Organoid, Esophageal Cancer, Chemoradiation
- Trial name
- RARESTEM/Org (NCT03283527)
- Where
- 3 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- University Medical Center Groningen
Esophageal Cancer
Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer
Elderly patients with esophageal cancer will receive thoracic radiation therapy 54-60Gy over 30 fractions, and concurrent with Gefitinib.
- Trial name
- NCT01291823
- Testing
- gefitinib, Thoracic radiotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer
Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer
RATIONALE: Laparoscopic-assisted surgery and video-assisted thoracoscopy are less invasive types of surgery for esophageal cancer that may have fewer side effects and improve recovery.
- Trial name
- NCT00063986
- Testing
- Minimally invasive esophagectomy (MIE)
- Where
- 41 sites in United States
- Volunteers
- 110 people
- Sponsor
- Eastern Cooperative Oncology Group
Esophageal Squamous Cell Carcinoma
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
The purpose of this study is to explore the safety and feasibility of anti-programmed cell death 1(PD-1) immunotherapy, Camrelizumab, combined with cyclin-dependent kinase 4/6 blockade, Palbociclib, as a new neoadjuvant treatment…
- Trial name
- NCT06654297
- Testing
- Camrelizumab, Palbociclib(100mg), Palbociclib(125mg)
- Where
- China
- Volunteers
- 6 people
- Sponsor
- West China Hospital
Pancreatic Cancer, Lung Cancer
Perceptions of Exceptional Patients in Cancer Care Relating to Their Unusual Survival
The main objective of this study is to explore experiences and insights from exceptional patients, patients with cancer that were considered by their physicians as having exceptional course of survival related to their specific…
- Conditions
- Pancreatic Cancer, Lung Cancer, Stomach Cancer, Esophageal Cancer
- Trial name
- NCT02055313
- Volunteers
- 20 people
- Sponsor
- Meir Medical Center
Esophageal Squamous Cell Carcinoma
Quantitative Assessment of Blood Supply in the Gastic Conduit With Fluorescence Angiography for Esophageal Reconstruction
A single-institution, randomize controlled trial is to be held to evaluate the correlation between blood supply in the gastic conduit and the incidence of anastomotic fistula during radical operation for esophageal squamous cell…
- Trial name
- NCT04229524
- Testing
- Fluorescence angiography
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Esophageal Cancer, Photodynamic Therapy
Hematoporphyrin Photodynamic Therapy for Esophageal Cancer
The objective of the present clinical trial is to assess the efficacy of photodynamic therapy (PDT) employing hematoporphyrin injection in the management of recurrent or residual superficial esophageal carcinoma.
- Trial name
- NCT06437288
- Testing
- photodynamic therapy
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Sun Yat-sen University
Renal Cell Carcinoma, Non Small Cell Lung Cancer
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
- Conditions
- Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC)
- Trial name
- PSI-Immune (NCT07223424)
- Testing
- nivolumab, pembrolizumab
- Where
- United States
- Volunteers
- 880 people
- Sponsor
- Diwakar Davar
Esophageal Cancer
A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer
The purpose of this study is to evaluate the investigators ability to obtain reliable and meaningful 11C-Choline PET-CT images of esophageal cancer.
- Trial name
- NCT01051479
- Testing
- C11-Choline
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Wake Forest University Health Sciences
Lung Neoplasms, Esophageal Neoplasms
The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I
Stage I of the Thoracic-POISE study will pilot-test a broad-based, multi-agent integrative care intervention delivered by naturopathic doctors in conjunction with standard surgical and oncologic care of people with thoracic…
- Conditions
- Lung Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- POISE (NCT02845479)
- Testing
- Integrative Care
- Where
- 2 sites in Canada
- Volunteers
- 22 people
- Sponsor
- The Canadian College of Naturopathic Medicine
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Stomach
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
This phase II trial is studying how well FR901228 works in treating patients with refractory stomach cancer or gastroesophageal junction.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer
- Trial name
- NCT00098527
- Testing
- romidepsin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.
- Trial name
- NCT04704154
- Testing
- Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
- Where
- 34 sites in United States, Belgium and 6 more
- Volunteers
- 175 people
- Sponsor
- Bayer
Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor…
- Conditions
- Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT07227168
- Testing
- STRO-004, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Sutro Biopharma, Inc.
Exercise Intervention
Pre- and Post-Operative Exercise Program in Upper Gastrointestinal Cancers
Esophageal and gastric cancers are a considerable health burden. In the past 10 years the 5-year survival for both cancers has doubled.
- Trial name
- PERIOP-OG (NCT03807518)
- Testing
- Standard Exercise Program
- Where
- Ireland
- Volunteers
- 72 people
- Sponsor
- Royal College of Surgeons, Ireland
Esophageal Cancer, Sleep Disturbance
Quality of Life After Esophagectomy for Cancer - Step 1
Background: A recent systematic review showed that patients undergoing esophagectomy for cancer had scores of physical function, vitality and performance of health in general significantly lower than those obtained from the…
- Conditions
- Esophageal Cancer, Sleep Disturbance, Quality of Life
- Trial name
- NCT01738620
- Testing
- psychological counseling, prevention of sleep disorders in ICU
- Where
- Italy
- Volunteers
- 74 people
- Sponsor
- University of Padova
OESOPHAGO-GASTRIC CARCINOMA, Oesophageal Adenocarcinoma
AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)
Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific.
- Conditions
- OESOPHAGO-GASTRIC CARCINOMA, Oesophageal Adenocarcinoma, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, Oesophageal Cancer Nos
- Trial name
- AROMA2 (NCT07260734)
- Testing
- Breath Test
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Barrett's Esophagus, Intestinal Metaplasia
Prevalence of Dysplasia of the Gastric Cardia
We propose a tissue sample collection study for patients at UNC who have undergone or will undergo radiofrequency ablation therapy for Barrett's Esophagus (BE) or intramucosal adenocarcinoma as part of routine medical care.
- Conditions
- Barrett's Esophagus, Intestinal Metaplasia, Intramucosal Adenocarcinoma
- Trial name
- NCT01787864
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- University of North Carolina, Chapel Hill
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
This is a phase I/II multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of investigational agents with pembrolizumab, plus chemotherapy or lenvatinib, for the treatment of participants with…
- Trial name
- NCT05342636
- Testing
- Pembrolizumab, Coformulation favezelimab/pembrolizumab, MK-4830
- Where
- 46 sites in Brazil, Chile and 11 more
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.